Tiina Skoog

Tiina Skoog

Auto-generated profile, based on publicly available information

Tiina Skoog

Department of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
NFNanna Fyhrquist
Nanna Fyhrquist
GMGareth Muirhead
Gareth Muirhead
SPStefanie Prast-Nielsen
Stefanie Prast-Nielsen
MJMarine Jeanmougin
Marine Jeanmougin
POPeter Olah
Peter Olah
HAHarri Alenius
Harri Alenius
Despite recent advances in understanding microbial diversity in skin homeostasis, the relevance of microbial dysbiosis in inflammatory disease is poorly understood. Here we perform a comparative analysis of skin microbial communities coupled to global patterns of cutaneous gene expression in patients with atopic dermatitis or psoriasis. The skin microbiota is analysed by 16S amplicon or whole genome sequencing and the skin transcriptome by microarrays, followed by integration of the data layers. We find that atopic dermatitis and psoriasis can be classified by distinct microbes, which differ from healthy volunteers microbiome composition. Atopic dermatitis is dominated by a single microbe (Staphylococcus aureus), and associated with a disease relevant host transcriptomic signature enriched for skin barrier function, tryptophan metabolism and immune activation. In contrast, psoriasis is characterized by co-occurring communities of microbes with weak associations with disease related gene expression. Our work provides a basis for biomarker discovery and targeted therapies in skin dysbiosis.

1 August 1999 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
TSTiina Skoog
Tiina Skoog
FHFerdinand M. Van'T Hooft
Ferdinand M. Van'T Hooft
BKBengt Kallin
Bengt Kallin
SJStefan Jovinge
Stefan Jovinge
SBSusanna Boquist
Susanna Boquist
AHAnders Hamsten
Anders Hamsten
Tumour necrosis factor-α (TNF-α) plays a key role in orchestrating the complex events involved in inflammation and immunity. Accordingly, TNF-α has been implicated in a wide range of autoimmune and infectious diseases, but also in conditions such as obesity and insulin resistance. The regulation of TNF-α expression in man is indicated to be partly genetically determined. We therefore screened a 1263 bp section of the proximal promoter of the TNF-α gene for common genetic variants affecting the transcriptional activity of the gene. Here we report the characterization of a common functional polymorphism in the promoter region of the TNF-α gene, a C→A substitution at position −863. Electromobility shift assays provided evidence for a distinct difference in the binding of monocytic and hepatic nuclear factors to the −863C and −863A alleles. The rare −863A allele was associated with 31% lower transcriptional activity (P < 0.001) in chloramphenicol acetyltransferase (CAT) reporter gene studies in human hepatoblastoma (HepG2) cells, indicating that the −863C/A polymorphism influences the basal rate of transcription of the TNF-α gene in vitro. Allele frequencies were 0.83/0.17 amongst 254 apparently healthy men of Swedish origin, aged 35–50 years. In 156 men, the −863C/A polymorphism was associated with the serum TNF-α concentration, carriers of the rare A allele having a significantly lower TNF-α level (P < 0.05). It is concluded that the common −863C/A polymorphism in the promoter region of the TNF-α gene is functional in vitro in monocytic and hepatic cells and influences the serum TNF-α concentration in vivo in healthy middle-aged men.

1 March 2002 in European Heart Journal
Verified
Journal Article
Open access
PDF file
TST. Skoog
T. Skoog
Wolfgang DichtlWolfgang Dichtl
Wolfgang Dichtl
SBS. Boquist
S. Boquist
CSC. Skoglund-Andersson
C. Skoglund-Andersson
FKF. Karpe
F. Karpe
AHA. Hamsten
A. Hamsten
Aims Tumour necrosis factor-α (TNF-α) is a proinflammatory cytokine, which is implicated in some metabolic disorders and may play a role in the devel

15 March 2016 in Scientific Reports
Verified
Journal Article
Open access
MTMari H. Tervaniemi
Mari H. Tervaniemi
SKShintaro Katayama
Shintaro Katayama
TSTiina Skoog
Tiina Skoog
HSH. Annika Siitonen
H. Annika Siitonen
JVJyrki Vuola
Jyrki Vuola
OEOuti Elomaa
Outi Elomaa
Psoriatic skin differs distinctly from normal skin by its thickened epidermis. Most gene expression comparisons utilize full-thickness biopsies, with substantial amount of dermis. We assayed the transcriptomes of normal, lesional and non-lesional psoriatic epidermis, sampled as split-thickness skin grafts, with 5′-end RNA sequencing. We found that psoriatic epidermis contains more mRNA per total RNA than controls and took this into account in the bioinformatic analysis. The approach highlighted innate immunity-related pathways in psoriasis, including NOD-like receptor (NLR) signaling and inflammasome activation. We demonstrated that the NLR signaling genes NOD2, PYCARD, CARD6 and IFI16 are upregulated in psoriatic epidermis and strengthened these findings by protein expression. Interestingly, PYCARD, the key component of the inflammasome, showed an altered expression pattern in the lesional epidermis. The profiling of non-lesional skin highlighted PSORS4 and mitochondrially encoded transcripts, suggesting that their gene expression is altered already before the development of lesions. Our data suggest that all components needed for the active inflammasome are present in the keratinocytes of psoriatic skin. The characterization of inflammasome pathways provides further opportunities for therapy. Complementing previous transcriptome studies, our approach gives deeper insight into the gene regulation in psoriatic epidermis.

13 March 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Audrey GalludAudrey Gallud
Audrey Gallud
KKKatharina Klöditz
Katharina Klöditz
JYJimmy Ytterberg
Jimmy Ytterberg
NÖNataliya Östberg
Nataliya Östberg
SKShintaro Katayama
Shintaro Katayama
BFBengt Fadeel
Bengt Fadeel
Systems biology is increasingly being applied in nanosafety research for observing and predicting the biological perturbations inflicted by exposure to nanoparticles (NPs). In the present study, we used a combined transcriptomics and proteomics approach to assess the responses of human monocytic cells to Au-NPs of two different sizes with three different surface functional groups,i.e., alkyl ammonium bromide, alkyl sodium carboxylate, or poly(ethylene glycol) (PEG)-terminated Au-NPs. Cytotoxicity screening using THP-1 cells revealed a pronounced cytotoxicity for the ammonium-terminated Au-NPs, while no cell death was seen after exposure to the carboxylated or PEG-modified Au-NPs. Moreover, Au-NR3+ NPs, but not the Au-COOH NPs, were found to trigger dose-dependent lethalityin vivoin the model organism,Caenorhabditis elegans. RNA sequencing combined with mass spectrometry-based proteomics predicted that the ammonium-modified Au-NPs elicited mitochondrial dysfunction. The latter results were validated by using an array of assays to monitor mitochondrial function. Au-NR3+ NPs were localized in mitochondria of THP-1 cells. Moreover, the cationic Au-NPs triggered autophagy in macrophage-like RFP-GFP-LC3 reporter cells, and cell death was aggravated upon inhibition of autophagy. Taken together, these studies have disclosed mitochondria-dependent effects of cationic Au-NPs resulting in the rapid demise of the cells.

1 May 2007 in Journal of Medical Genetics
Verified
Journal Article
Closed access
PDF file
AHAnna Hellquist
Anna Hellquist
MZMarco Zucchelli
Marco Zucchelli
KKKatja Kivinen
Katja Kivinen
USUlpu Saarialho-Kere
Ulpu Saarialho-Kere
SKSari Koskenmies
Sari Koskenmies
CLCecilia Lindgren
Cecilia Lindgren
Background: Several members of the GIMAP gene family have been suggested as being involved in different aspects of the immune system in different species. Recently, a mutation in the GIMAP5 gene was shown to cause lymphopenia in a rat model of autoimmune insulin-dependent diabetes. Thus it was hypothesised that genetic variation in GIMAP5 may be involved in susceptibility to other autoimmune disorders where lymphopenia is a key feature, such as systemic lupus erythematosus (SLE). Material and methods: To investigate this, seven single nucleotide polymorphisms in GIMAP5 were analysed in five independent sets of family-based SLE collections, containing more than 2000 samples. Result: A significant increase in SLE risk associated with the most common GIMAP5 haplotype was found (OR 1.26, 95% CI 1.02 to 1.54, p = 0.0033). In families with probands diagnosed with trombocytopenia, the risk was increased (OR 2.11, 95% CI 1.09 to 4.09, p = 0.0153). The risk haplotype bears a polymorphic polyadenylation signal which alters the 3′ part of GIMAP5 mRNA by producing an inefficient polyadenylation signal. This results in higher proportion of non-terminated mRNA for homozygous individuals (p<0.005), a mechanism shown to be causal in thalassaemias. To further assess the functional effect of the polymorphic polyadenylation signal in the risk haplotype, monocytes were treated with several cytokines affecting apoptosis. All the apoptotic cytokines induced GIMAP5 expression in two monocyte cell lines (1.5–6 times, p<0.0001 for all tests). Conclusion: Taken together, the data suggest the role of GIMAP5 in the pathogenesis of SLE.